29 results on '"Abdelrahim Maen"'
Search Results
2. Real-world (RW) experience with atezolizumab + bevacizumab (A+B) for the treatment of unresectable HCC (uHCC): A multicenter study.
3. Feasibility of disease recurrence monitoring in liver post-transplantation for patients with hepatocellular carcinoma via personalized and tumor-informed ctDNA test.
4. Outcomes of patients with advanced urothelial cancer who develop infection while on treatment with pembrolizumab.
5. The impact of pembrolizumab on patients with pre-existing autoimmune diseases.
6. Combination of transarterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) compared to TACE alone as bridging therapy transplant recipients with hepatocellular carcinoma: An update.
7. Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation.
8. Prognostic value of molecular response via ctDNA measurement in predicating response of systemic therapy in patients with advanced solid cancer.
9. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
10. Comparative molecular profiling of pancreatic ductal adenocarcinoma (PDAC) of the head (H) versus body/tail (B/T) and the tumor immune microenvironment (TIME).
11. Minimal residual disease assessment in colorectal cancer (MiRDA-C).
12. Real-world experience of pancreatic cancer molecular profiling in a tertiary center.
13. Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.
14. A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.
15. Use of pulse steroids to treat renal IRAE to maintain patients with metastatic non-small cell carcinoma cancer on pembrolizumab.
16. Hepatitis B reactivation with pembrolizumab, atezolizumab, and nivolumab: A pharmacovigilance study and literature review.
17. Checkpoint inhibitors related renal vasculitis and use of rituximab.
18. Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival.
19. Development and validation of a risk assessment tool for symptomatic BKV infection.
20. Checkpoint inhibitor induced glomerulonephritis.
21. Allo-immunity and graft rejection after checkpoint inhibitor therapy (CPI) in solid organ transplant (SOT) recipients.
22. A validated symptomatic BKV risk assessment score in patient post allogeneic stem cell transplant.
23. Survival benefits among patients with end-stage renal disease receiving dialysis versus no dialysis.
24. Symptomatic BK virus as a significant independent predictor of immune suppression and poor overall survival in allogeneic hematopoietic stem cell recipients.
25. BK virus as a predictor of chronic kidney disease in hematopoietic stem cell recipients.
26. Circulating tumor DNA (ctDNA) and disease recurrence in early stage pancreatic cancer.
27. Genomic profiling of biliary tract carcinomas by their location.
28. Inactivation of the nuclear receptor TR3 as an important new drug target for treating RCC.
29. Survival benefits among patients with end-stage renal disease receiving dialysis versus no dialysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.